Impact of Obicetrapib on Major Adverse Cardiovascular Events: a Pooled Analysis of Phase 3 Clinical Trials

NewAmsterdam Pharma Company NV published this content on September 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 01, 2025 at 09:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]